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Mantle cell lymphoma (MCL) 1 is characterized by dysregulated expression of cyclin D1 due to the cytogenetic translocation t(11;14)(q13;q32). 2 Cyclin D1 interaction with cyclin-dependent kinases (cdk) drives cells through the G1-S checkpoint. Nonetheless, cyclin D1 overexpression in mouse B cells is not sufficient to induce lymphoma and cyclin D1 is necessary, but not sufficient, to produce MCL. 3 While therapeutic advances have prolonged survival in MCL, 4 with many novel agents in development, optimizing combinations would benefit from an animal model. MCL cell lines generally represent blastoid or atypical variants. 5 Two recently reported mouse models of blastoid MCL, one based on interleukin-14/myc double transgenics, 6 the other on combined abnormalities of INK4A and myc, 7 may provide biological insights and testing for blastoid MCL. Transgenic mice expressing cyclin D1 in B cells are healthy. 3 We previously demonstrated that these mice do develop lymphoma with MCL characteristics if their immune system is non-specifically stimulated by pristane when they are older. 8 This system can provide biologic insights into genetic events cooperating with cyclin D1. 9 Unfortunately, the aging requirement makes this model cumbersome for therapeutic testing. Here we report that the FC-muMCL1 cell line established from a pristane-induced lymphoma, grows in young syngeneic mice, has associated immune cell infiltration, and provides a means to test novel targeted therapies against lymphomas constitutively overexpressing cyclin D1. 10 FC-muMCL1 originated from splenocytes of a 1-year-old male Em-cyclin D1 transgenic C57Bl6 mouse injected intraperitoneally with pristane monthly Â 3 as previously described. 8 Initially cultured in RPMI 1640 þ 20% heat-inactivated fetal bovine serum (FBS), 2 mM glutamine/l, 100 units/ml penicillin, 100 g/ml streptomycin, 1 mM Na-pyruvate (Sigma-Aldrich, St Louis, MO, USA), 0.1 mM non-essential amino acids (Cellgro, Mediatech Inc., Manassas, VA, USA), supplemented with 8 mg/ml adenosine, 8.5 mg/ml guanosine, 7.3 mg/ml uridine, 7.3 mg/ml cytidine, 2.4 mg/ ml thymidine, 25 mg/ml insulin, 10 mg/ml transferrin, 0.2 nM T3 and 100 mM mercaptoethanolamine, eventually media was changed to RPMI1640 þ 15% FBS without supplements. Cells treated with rapamycin or bortezomib were analyzed for growth by MTS assay and for apoptosis by annexin V-propidium iodide staining and flow cytometry as before. 11 Flow cytometric immunophenotyping for B220 (CD45), CD19, CD23 and CD5, and for IgM, IgD, k and l was performed as before. 11 Karyotypic analysis and array comparative genomic hybridization (aCGH) were performed as previously described. 12, 13 Briefly, cytogenetic analysis of actively proliferating FC-muMCL1 cells was performed by exposing cells to colcemid (Gibco, Grand Island, NY, USA) for 2 h, suspending in 0.075 M KCl for 18 min at 37 1C, and fixing in Carnoy's fixative (3:1, methanol:acetic acid, Fisher). Preparation of metaphase spreads, and G-banding was performed using standard procedures and karyotyped according to International Society for Cytogenetic Nomenclature (2009). Chromosome identification and karyotype designations were in accordance with University of Washington guidelines (http://www.pathology.washington.edu/research/cytopages/idiograms/ mouse/) and aCGH using Agilent's DNA microarray-based technology (Agilent, Santa Clara, CA, USA) was performed (Genomic Core Facility, Fox Chase Cancer Center).
RNA was isolated (Genomic Core) by Trizol (Invitrogen, Carlsbad, CA, USA), further purified by RNeasy kit (Qiagen, Valencia, CA, USA), and RNA purity and integrity evaluated using an Agilent 2,100 Bioanalyzer and Nanodrop 1000 (Nanodrop Technologies, Wilmington, DE, USA). RNA was prepared from four independently isolated FC-muMCL cell lines and from splenic B cells as a comparator. Splenic B cells were purified from 15-month-old Emcyclin D1 transgenic C57Bl6 mice by Miltenyi CD19 magnetic beads (Miltenyi, Auburn, CA, USA). Total RNA (50-200 ng) was amplified and labeled using Agilent Low Input QuickAmp labeling kit following the manufacturer's protocol. This Cy-3 labeled cRNA target (1.65 mg) was hybridized onto Agilent 4 Â 44 k whole genome array (65 1C for 17 h) and washed per Agilent procedure. Hybridized slides are scanned at 5-mm resolution on the Agilent scanner and fluorescent intensities of hybridization signals extracted using Agilent Feature Extraction software.
FC-muMCL1 (1 Â 10 7 /0.2 ml phosphate-buffered saline) were injected intraperitoneally into immunocompetent C57Bl6 or Fox Chase C.B.17 scid mice. C57Bl6 mice were preconditioned with 150 mg/kg subcutaneous cyclophosphamide 48-72 h prior. Mice were observed thrice weekly and sacrificed when they appeared ill, on an institutionally approved protocol. Visible tumor occurs in about 4 weeks in C57Bl6 mice and within days in scid mice. Tissues were processed for histopathology and immunohistochemistry as before. portions of chromosomes 4, 8 and 11 and the distal portion of 16, suggesting that the cytogenetic markers are derived from parts of these chromosomes. The cells also showed loss of one copy of chromosome 13 and focal deletions on chromosomes 6, 11, 12 and 14 encompassing the genes Igk, Nalp1b/Nalp1c, IgH and Fhit, respectively.
Within 4-6 weeks of intraperitoneal injection of FC-muMCL1 cells in C57Bl6 mice, a disseminated B-cell lymphoma with aggressive histologic appearance (Figure 2 ) involved virtually all organs, including the gastrointestinal tract. Spleen and lymph nodes were enlarged and diffusely infiltrated with lymphoma, without grossly visible lymphoma nodules. In mice with more extensive systemic tumor, meningeal involvement occurred. Immunohistochemistry documented that the resulting lymphomas retained the cell line markers, being CD5 þ B cells expressing cyclin D1. CD5 expression was confirmed by immunoblot analysis (not shown). Macrophages identified by MAC1 staining are plentiful (Figure 2b) , and CD3 stain demonstrates that small T cells also infiltrate the lymphoma (Figure 2d) .
Em-cyclin D1 transgenic C57Bl6 mice are healthy, developing lymphoma only when older transgenic mice are treated with pristane. 8 To determine genetic events induced in older mice by pristane that cooperate with cyclin D1 in lymphomagenesis, we isolated and pooled RNA from FC-muMCL1 and three additional cell lines established from separate pristane-induced lymphomas. As a comparator, we used RNA from splenic B cells from nonpristane treated age-matched Em-cyclin D1 transgenic C57Bl6 mice. Microarray comparisons of these two pools of RNA indicated multiple up-and downregulated genes (data not shown). A more limited set of micro-RNA (miRNA) changes were detected, many reflecting modestly increased expression. Only three miRNAs, miR-150, miR-181b and miR-340-5p, were significantly downregulated, suggesting possible tumor suppressor functions for these miRNA. The best characterized of these, miR-150, regulates c-myb in B cells.
14 Thus, miR150 downregulation should upregulate c-myb. Myb is indeed expressed in fresh lymphomas in our model, as well as in FC-muMCL1 (Figure 1b) .
To determine whether FC-muMCL1 are sensitive to biologically targeted agents active in MCL, we utilized the mammalian target of rapamycin inhibitor rapamycin and the proteasome inhibitor bortezomib. For bortezomib at 48 h, the IC 50 is about 5 nM, and apoptosis is induced (Figure 1c) . Rapamycin has similar effects with the IC 50 being about 1 nM (data not shown).
The poor overall outcome of MCL is improving, 4 but curative therapy remains elusive. Biologically targeted agents are active in MCL, and a significant challenge is to rationally select and develop effective therapeutic combinations, given a multitude of possibilities and relatively few patients. In such circumstances, animal models, despite their limitations, can be useful. The field has relied on established cell lines 5 of limited applicability to classic MCL. More recently, human MCL xenografts 15 and two mouse models of blastoid MCL driven by myc plus another abnormality have been reported. 6, 7 Our pristane-stimulated older Em-cyclin D1 mouse model has MCL features and may be useful in understanding lymphomagenesis, 8 but is cumbersome for testing therapeutics. Our transplantable cell line derived from this model retains the MCL immunophenotype (cyclin D1 þ , CD5 þ , CD23 À B cells), responds to clinically effective treatments and grows in syngeneic mice. This model will be valuable for preclinical testing of novel therapeutic agents, including those acting through immunomodulatory mechanisms, 10 and exploring combination therapy. This animal model and derived cell lines can provide insights into molecular pathways that cooperate with cyclin D1 dysregulation in mantle cell lymphomagenesis. We have already found HIP1 as an important upregulated protein in lymphoma. 9 Micro-RNA profiles suggest that a limited number of downregulated miRNA species may be important in this process. Targets of the miRNAs identified, such as c-myb, may have an unexpected role in MCL. The FC-muMCL1 cell line provides the opportunity to readily test novel agents and combinations preclinically both in vitro and in vivo. Determinants of response and resistance should be definable. Because these cells grow in immunocompetent syngeneic mice, and T cells and 
